Modern approaches to treating chronic myelogenous leukemia

Current Oncology Reports

Volumn 10, Issue 5, 2008, Pages 365-371

  Pinilla Ibarz, Javier ^a   Bello, Celeste ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ALPHA INTERFERON; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BILIRUBIN; BOSUTINIB; CANCER VACCINE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; NILOTINIB; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; PHA 739358; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN PR1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN WT 1; QS 21; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228; ABELSON KINASE; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATITIS; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FOLLOW UP; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; LONG TERM CARE; MALIGNANT TRANSFORMATION; MONOTHERAPY; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHARMACOGENETICS; PLEURA EFFUSION; PLURIPOTENT STEM CELL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TARGET CELL DESTRUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; DRUG ANTAGONISM; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; ONCOLOGY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL ONCOLOGY; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR; PYRIMIDINES; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 55749100536     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0057-0     Document Type: Review

References (52)

1. Faderl S, Talpaz M, Estrov Z, et al.: The biology of chronic myeloid leukemia. N Engl J Med 1999, 341: 164-172.
2. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346: 645-652.
3. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348: 994-1004.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247: 1079-1082.
5. Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000, 96: 3343-3356.
6. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344: 1031-1037.
7. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002, 99: 3530-3539.
8. Druker BJ, Guilhot F, O'Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355: 2408-2417.
9. Hochhaus A, Druker BJ, Larson R, et al.: IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed CML in chronic phase treated with imatinib [abstract 25]. Blood 2007, 110: 15a.
10. Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293: 876-880.
11. Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305: 399-401.
12. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354: 2531-2541.
13. Stone R, Kantarjian H, Baccarani M, et al.: Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) [abstract]. Blood 2007, 110: 734.
14. Kantarjian HM, Rousselot P, Pasquini R, et al.: Dasatinib or high-dose imatinib for patients with chronic phase CML resistant to standard dose imatinib: 2-year follow up data from START-R [abstract 736]. Blood 2007, 110: 226a.
15. Guilhot F, Apperley JF, Kim D, et al.: Efficacy of dasatinib in patients with accelerated phase CML with resistance or intolerance to imatinib: 2 year follow up data from START-A [abstract 470]. Blood 2007, 110: 145a.
16. Gambacorti C, Cortes J, Kim D, et al.: Efficacy and safety of dasatinib in patients with CML in blast crisis whose disease is resistant or intolerant to imatinib: 2 year follow up data from the START program [abstract 472]. Blood 2007, 110: 145a.
17. Bristol-Myers Squibb: Clinical study report for study CA180-034. Available at http://ctr.bms.com/ctd/InitTrialDetailAction.do?pnum= CA180-034. Accessed May 5, 2008.
18. Atallah EL, Kantarjian H, O'Brien S, et al.: Use of dasatinib in patients with previously untreated CML in chronic phase [ASCO abstract]. J Clin Oncol 2007, 25(18S): 7005.
19. Golemovic M, Verstovsek S, Giles F, et al.: AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukaemia. Clin Cancer Res 2005, 11: 4941-4947.
20. O'Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65: 4500-4505.
21. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354: 2542-2551.
22. National Cancer Institute: FDA approval for nilotinib. Available at http://www.cancer.gov/cancertopics/druginfo/fda-nilotinib. Accessed June 3, 2008.
23. Le Coutre P, Ottman OG, Giles F, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or - intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111: 1834-1839.
24. Cortes J, O'Brien S, Jabbour E, et al.: Efficacy of nilotinib (AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome positive CML in early chronic phase [abstract]. Blood 2007, 110: 29.
25. Puttini M, Coluccia AM, Boschelli F, et al.: In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL+ neoplastic cells. Cancer Res 2006, 66: 11314-11322.
26. Gambacorti-Passerini C, Brummendorf T, Kantarjian H, et al.: Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib [ASCO abstract]. J Clin Oncol 2007, 25(18S): 7006.
27. Cortes J, Brummendorf T, Kantarjian H, et al.: Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) [abstract]. Blood 2007, 110: 733.
28. Gambacorti-Passerini C, Kantarjian H, Brummendorf T, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ All [abstract]. Blood 2007, 110: 473.
29. Naito H, Kimura S, Nakaya Y, et al.: In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 2006, 30: 1443-1446.
30. Kantarjian J, Cortes J, Le Coutre P, et al.: A phase I study of INNO-406 in patients with advanced Ph+ leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors [abstract]. Blood 2007, 110: 469.
31. Yokota A, Kimura S, Masuda S, et al.: INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007, 109: 306-314.
32. Shah N, Kasap C, Paquette R, et al.: Targeting drug resistant CML and Ph+ ALL with the spectrum selective protein kinase inhibitor XL228 [abstract 474]. Blood 2007, 110: 146a.
33. Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001, 2: 21-32.
34. Giles FJ, Cortes J, Jones D, et al.: MK-0457, a novel kinase inhibitor, is active in patients with CML or ALL with the T315I mutation. Blood 2007, 109: 500-502.
35. Paquette L, Shah NP, Sawyers CL, et al.: PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract 1030]. Blood 2007, 110: 312a.
36. Tauchi T, Akahane D, Nunoda K, et al.: Combined effects of a Pan-Aurora kinase inhibitor MK-0457 and dasatinib against T315I mutant form of BCR-ABL: In vitro and in vivo studies [abstract]. Blood 2007, 110: 805.
37. Strauss A, Chu S, Holyoake T, et al.: Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib [abstract]. Blood 2007, 110: 1031.
38. Copland M, Pellicano F, Richmond L, et al.: BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008, 111: 2843-2853.
39. Pinilla-Ibarz J, Cathcart K, Scheinberg D: CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 2000, 14: 111-120.
40. Bocchia M, Korontsvit T, Xu Q, et al.: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996, 87: 3587-3592.
41. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al.: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000, 95: 1781-1787.
42. Cathcart K, Pinilla-Ibarz J, et al.: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103: 1037-1042.
43. Bocchia M, Gentili S, Abruzzese E, et al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005, 365: 657-662.
44. Rojas JM, Knight K, Wang J, Clark RE: Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: Results of the EPIC study. Leukemia 2007, 21: 2287-2295.
45. Pinilla-Ibarz J, May RJ, Korontsvit T, et al.: Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006, 20: 2025-2033.
46. May RJ, Dao T, Pinilla-Ibarz J, et al.: Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007, 1: 4547-4555.
47. Maslak P, Daao T, Gomez M, et al.: A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008 Feb 7 (Epub ahead of print).
48. Smith B, Kasamon YL, Miller CB, et al.: K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (pts) with residual disease on imatinib mesylate (IM) [ASCO abstract]. J Clin Oncol 2006, 24(18S): 6509.
49. Marin D, Mauro M, Goldman J, et al.: Preliminary results from a phase 2 trial of AG-858, an autologous heat shock protein-peptide vaccine, in combination with imatinib in patients with chronic phase chronic myeloid leukemia (CML) resistant to prior imatinib monotherapy [abstract]. Blood 2005, 10: 1094.
50. Rezvani K, Yong AS, Mielke S, et al.: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111: 236-242.
51. Rusakiewicz S, Molldrem JJ: Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 2006, 18: 599-604.
52. Oka Y, Tsuboi A, Elisseeva OA, et al.: WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Scientific WorldJournal 2007, 7: 649-665.